AcryMed Wins Honor Highlighting Innovative Nano Technology

SilvaGard® Technology Can Have A Direct Impact On Hospital-Related Infections And Save Thousands of Lives Each Year.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Portland, Oregon (PRWEB) November 3, 2005

AcryMed, a medical device company specializing in wound care and infection-fighting technology, today announced they were selected as Emerging NanoBusiness Showcase (ENBS) winners at this year’s NanoCommerce & SEMI NanoForum held November 1-3 in Chicago. The forum is widely recognized as the largest business oriented nanotech show in North America. The ENBS highlights companies that have revolutionary technologies, innovative applications and compelling commercialization strategies related to nanotechnology breakthroughs.

ENBS presenters are selected by a panel of distinguished corporate executives and venture capitalists specializing in nanotechnology and related industries. According to forum officials, the winning companies are developing technologies that are most likely to change our lives in a meaningful and profound way.

To this regard, AcryMed’s SilvaGard technology allows medical device manufacturers for the first time to effectively and uniformly apply antimicrobial silver to the surface of any medical device without changing any of the physical characteristics of the device. The antimicrobial coating makes the device resistant to bacteria and therefore halts the transmission of infections from the device to patient. According to Dr. Bruce Gibbins PhD, founder and CTO of AcryMed, this capability will have an enormous impact on one of the most pressing concerns of modern day medicine.

“There are two million hospital acquired infections annually in this country -- 90, 000 result in death,” said Gibbins. “More than half of these infections are associated with catheters and other percutaneous devices that provide a support surface for organisms to track into deeper tissue. A typical infection can cost as much as $47,000 per patient to treat. Our SilvaGard technology provides a legitimate solution to many of these hospital related, life threatening infections by preventing the formation of biofilms on medical devices.”

SilvaGard has already been licensed for its first medical device application and is currently in production.

SilvaGard is a new technology developed by AcryMed based on years of work with silver antimicrobial applications. AcryMed’s SilvaSorb® wound dressings and SilvaSorb gel are recognized worldwide in the advanced wound care industry. The company was founded in 1993 by Dr. Gibbins who obtained his Ph.D. in Bacteriology and Public Health from Washington State University.

AcryMed (http://www.acrymed.com) is based in Portland, Oregon where it maintains GMP manufacturing and GLP lab facilities. The company is ISO certified and operates under ISO 13485 and EN 93/42/EEC.

###


Contact